Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials

In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs). Although noninferiority was the rule in phase-3 RCTs...

Descripción completa

Detalles Bibliográficos
Autores principales: Giacobbe, Daniele Roberto, Vena, Antonio, Falcone, Marco, Menichetti, Francesco, Bassetti, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598297/
https://www.ncbi.nlm.nih.gov/pubmed/36290023
http://dx.doi.org/10.3390/antibiotics11101365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598297/
https://www.ncbi.nlm.nih.gov/pubmed/36290023
http://dx.doi.org/10.3390/antibiotics11101365

Ejemplares similares